Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Certified by Founder
Lodge
ADARx Pharmaceuticals Inc.
start up
United States
- San Diego, CA
- 10/08/2023
- Series C
- $200,000,000
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms.
ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.
- Industry Biotechnology Research
- Website https://www.adarx.com/
- LinkedIn https://www.linkedin.com/company/adarx-pharmaceuticals-inc/
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)